Hugo M. Prazeres

Porto, 4200135, Portugal

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Targeting under-screened women in cervical cancer: combining self-sampling and human papillomavirus testing with a strategic reminder plan.

Targeting under-screened women in cervical cancer: combining self-sampling and human papillomavirus testing with a strategic reminder plan.

Journal: European journal of public health

Published: July 29, 2025

TERTmonitor Efficacy and Performance in Detecting Mutations by Droplet Digital PCR.

TERTmonitor Efficacy and Performance in Detecting Mutations by Droplet Digital PCR.

Journal: Genes

Published: October 11, 2024

Corrigendum: Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal - U-PIK Project.

Corrigendum: Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal - U-PIK Project.

Journal: Frontiers in molecular biosciences

Published: September 21, 2023

TERTmonitor-qPCR Detection of TERTp Mutations in Glioma.

TERTmonitor-qPCR Detection of TERTp Mutations in Glioma.

Journal: Genes

Published: July 21, 2023

Using a Dual CRISPR/Cas9 Approach to Gain Insight into the Role of LRP1B in Glioblastoma.

Using a Dual CRISPR/Cas9 Approach to Gain Insight into the Role of LRP1B in Glioblastoma.

Journal: International journal of molecular sciences

Published: June 04, 2023

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal - U-PIK Project.

Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal - U-PIK Project.

Journal: Frontiers in molecular biosciences

Published: October 28, 2022

LRP1B: A Giant Lost in Cancer Translation.

LRP1B: A Giant Lost in Cancer Translation.

Journal: Pharmaceuticals (Basel, Switzerland)

Published: July 25, 2021

Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.

Resistance to endocrine therapy in HR + and/or HER2 + breast cancer: the most promising predictive biomarkers.

Journal: Molecular biology reports

Published: April 24, 2021

LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer.

LRP1B Expression as a Putative Predictor of Response to Pegylated Liposomal Doxorubicin Treatment in Ovarian Cancer.

Journal: Pathobiology : journal of immunopathology, molecular and cellular biology

Published: March 17, 2021

Clinical Validation of a Urine Test (Uromonitor-V2®) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients.

Clinical Validation of a Urine Test (Uromonitor-V2®) for the Surveillance of Non-Muscle-Invasive Bladder Cancer Patients.

Journal: Diagnostics (Basel, Switzerland)

Published: August 14, 2020

Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer.

Predictive Biomarkers and Patient Outcome in Platinum-Resistant (PLD-Treated) Ovarian Cancer.

Journal: Diagnostics (Basel, Switzerland)

Published: June 19, 2020

Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review.

Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review.

Journal: Diagnostics (Basel, Switzerland)

Published: December 17, 2019

Showing 1-12 of 27

Last Updated: 09/26/2026